Castleark Management’s Krystal Biotech KRYS Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$5.43M Buy
16,320
+170
+1% +$58.9K 0.14% 150
2026
Q2
$6M Sell
16,150
-15,480
-49% -$4.63M 0.16% 146
2026
Q1
$8.17M Buy
31,630
+2,370
+8% +$631K 0.27% 87
2025
Q4
$7.21M Buy
+29,260
New +$6.16M 0.21% 114
2025
Q2
– Sell
-26,120
Closed -$4.71M – 310
2025
Q1
$4.71M Buy
+26,120
New +$4.39M 0.16% 129
2024
Q4
– Sell
-27,290
Closed -$4.97M – 308
2024
Q3
$4.97M Sell
27,290
-990
-4% -$191K 0.2% 123
2024
Q2
$5.19M Sell
28,280
-240
-0.8% -$40.3K 0.21% 111
2024
Q1
$5.07M Sell
28,520
-3,830
-12% -$532K 0.21% 116
2023
Q4
$4.01M Buy
32,350
+20,930
+183% +$2.32M 0.18% 136
2023
Q3
$1.32M Buy
+11,420
New +$1.39M 0.07% 181

Other funds holding KRYS

Castleark Management's KRYS Position: Q3 2026 in Review

Castleark Management increased its Krystal Biotech (KRYS) stake by 1.1% in Q3 2026, buying an estimated $58.9K and bringing the position to 16,320 shares worth $5.43M. The position accounts for 0.14% of the portfolio, ranked #150.

Castleark Management first reported a position in KRYS in Q3 2023 and has held it in 10 quarters since. The position peaked at $8.17M in Q1 2026. 442 funds tracked by Wall St. Rank hold KRYS as of Q3 2026.

  • Castleark Management held 16,320 shares of Krystal Biotech worth $5.43M as of Q3 2026.
  • Castleark Management bought 170 Krystal Biotech shares in Q3 2026, an estimated $58.9K.
  • Krystal Biotech made up 0.14% of Castleark Management's portfolio in Q3 2026, its #150 holding.
  • Castleark Management first reported a position in Krystal Biotech in Q3 2023 and has held it in 10 quarters since.
  • Castleark Management's Krystal Biotech position peaked at $8.17M in Q1 2026.
  • 442 funds tracked by Wall St. Rank held Krystal Biotech as of Q3 2026.

Based on Castleark Management's 13F filing for Q3 2026, filed 16 Nov 2026.